

10/510,275

=> d his

(FILE 'HOME' ENTERED AT 09:57:38 ON 14 NOV 2007)

FILE 'REGISTRY' ENTERED AT 09:57:50 ON 14 NOV 2007

L1 STRUCTURE UPLOADED
L2 9 S L1
L3 469 S L1 SSS FUL
L4 449 S L3 AND CAPLUS/LC
L5 20 S L3 NOT L4


FILE 'CAPLUS' ENTERED AT 09:58:59 ON 14 NOV 2007

L6 16 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total


L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2007:257667 CAPLUS
 DOCUMENT NUMBER: 146:295786
 TITLE: Preparation of dibenzo[c,f]pyrido[1,2-a]azepine derivatives as glucocorticoid receptor modulators
 INVENTOR(S): Plate, Ralf; Jans, Christiaan Gerardus Johannes Maria
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 46pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007025938	A1	20070308	WO 2006-EP65696	20060825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: EP 2005-107896 A 20050829

OTHER SOURCE(S): MARPAT 146:295786

GI



I



II

AB Title compds. I [R1 and R10 independently = H or alkyl; R2 = CHO, SO₂H, (un)substituted alkylC(O), etc.; R3 and R4 independently = H, alkyl, OH, alkoxy, etc.; R6 = H or R16ONC(R16), R16 = H, alkyl, alkenyl or alkynyl; R7 = H, halo, CN, (un)substituted alkyl, etc.; R8 = H, CN, halo, NO₂, etc.; R9 = H, halo, CN, alkyl with provision that substituents = halo; R11 = H; R12 = H, CN or alkyl; R13 = H, alkyl, halo or CHO; R14 = H, halo, CN,

alkyl or (hetero)aryl], and their pharmaceutically acceptable salts, are prepared and disclosed as glucocorticoid receptor modulators. Thus, e.g., a multi-step synthesis of II, starting from anthraquinone was given. Glucocorticoid receptor binding activity for I was determined as $< 2 \times 10^{-8}$ M. I as glucocorticoid receptor modulators may be used for treating inflammatory diseases.


IT 928245-53-8P 928245-55-0P 928245-59-4P
928245-75-4P 928245-79-8P 928246-07-5P
928246-19-9P 928246-27-9P 928246-33-7P
928246-78-0P 928246-84-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of dibenzo[c,f]pyrido[1,2-a]azepine derivs. as glucocorticoid receptor modulators)

RN 928245-53-8 CAPLUS

CN Acetamide, N-[(2R,10R,14bR)-8-bromo-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-55-0 CAPLUS

CN Acetamide, N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-59-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-75-4 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-8-acetyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-79-8 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-07-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-19-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-27-9 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-33-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-78-0 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylic acid, 1,2,3,4,10,14b-hexahydro-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-84-8 CAPLUS


CN Acetamide, N-[(2R,10R,14bR)-8-(6-chloro-4-pyrimidinyl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 928245-57-2P 928245-61-8P 928245-63-0P
 928245-65-2P 928245-67-4P 928245-69-6P
 928245-71-0P 928245-73-2P 928245-77-6P
 928245-82-3P 928245-84-5P 928245-86-7P
 928245-88-9P 928245-90-3P 928245-93-6P
 928245-95-8P 928245-98-1P 928245-99-2P
 928246-01-9P 928246-03-1P 928246-05-3P
 928246-09-7P 928246-11-1P 928246-13-3P
 928246-15-5P 928246-17-7P 928246-21-3P
 928246-23-5P 928246-25-7P 928246-29-1P
 928246-31-5P 928246-35-9P 928246-36-0P
 928246-38-2P 928246-40-6P 928246-42-8P
 928246-44-0P 928246-46-2P 928246-48-4P
 928246-50-8P 928246-52-0P 928246-54-2P
 928246-56-4P 928246-58-6P 928246-60-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



RN 928245-65-2 CAPLUS

CN Methanesulfonamide, N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-67-4 CAPLUS


CN Ethanesulfonamide, N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928245-69-6 CAPLUS
 CN Sulfamide, N'-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928245-71-0 CAPLUS
 CN 4-Isoxazolecarboxamide, N'-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-3,5-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 928245-73-2 CAPLUS
 CN Acetamide, N'-[(2R,10R,14bR)-8-acetyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928245-77-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-8-[1-(hydroxyimino)ethyl]-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 928245-82-3 CAPLUS

CN Acetamide, 2,2-dichloro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-84-5 CAPLUS

CN Acetamide, 2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-86-7 CAPLUS

CN Acetamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-88-9 CAPLUS

CN 5-Isioxazolecarboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-90-3 CAPLUS


CN 3-Isioxazolecarboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-5-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928245-93-6 CAPLUS
 CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 928245-95-8 CAPLUS
 CN 2-Thiopheneacetamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928245-98-1 CAPLUS

CN Methanesulfonamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928245-99-2 CAPLUS

CN Ethanesulfonamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/510,275



RN 928246-01-9 CAPLUS

CN Sulfamide, N'-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N,N-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-03-1 CAPLUS

CN Acetamide, 2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-05-3 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, 4-amino-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-09-7 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-11-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-pyrazinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-13-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylic acid, 1,2,3,4,10,14b-hexahydro-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, methyl ester, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-15-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylic acid, 1,2,3,4,10,14b-hexahydro-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, ethyl ester, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-17-7 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxylic acid, 1,2,3,4,10,14b-hexahydro-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, propyl ester, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-21-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-10-methyl-N-4-pyridinyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-23-5 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-N-(2-methoxy-5-pyrimidinyl)-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928246-25-7 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-N-(2-methoxyphenyl)-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 928246-29-1 CAPLUS
 CN Acetamide, 2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-31-5 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-35-9 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-pyridinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-36-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-38-2 CAPLUS

CN Acetamide, 2,2-dichloro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-40-6 CAPLUS

CN Methanesulfonamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-42-8 CAPLUS

CN Acetamide, 2-chloro-2,2-difluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-44-0 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, 2-amino-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyrimidinyl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,5-dihydro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928246-46-2 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,4S,10R,14bR)-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/510,275



RN 928246-48-4 CAPLUS

CN Urea, N'-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-N-methoxy-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-50-8 CAPLUS

CN Acetamide, N'-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2-hydroxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-52-0 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 2-
[[dimethylamino]carbonyl]amino]-1,2,3,4,10,14b-hexahydro-10-methyl-N-
phenyl-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-54-2 CAPLUS

CN Acetamide, N-[(2R,10R,14bR)-8-(4,5-dihydro-2-oxazolyl)-1,2,3,4,10,14b-
hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-2,2,2-trifluoro-,
rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-56-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-58-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-8-formyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 928246-60-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-8-[1-(hydroxyimino)ethyl]-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



IT 928246-91-7 928246-93-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of dibenzo[c,f]pyrido[1,2-a]azepine derivs. as glucocorticoid receptor modulators)

RN 928246-91-7 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-93-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-4,10-dimethyl-, (2R,4S,10R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 928246-68-8P 928246-70-2P 928246-72-4P

928246-74-6P 928246-76-8P 928246-80-4P

928246-82-6P 928246-86-0P 928246-88-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzo[c,f]pyrido[1,2-a]azepine derivs. as glucocorticoid receptor modulators)

RN 928246-68-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 8-bromo-10,14b-dihydro-10-methyl-, (10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-70-2 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-ol, 8-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,10S,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-72-4 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine, 2-azido-8-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,10R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/510,275

RN 928246-74-6 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-76-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carbonitrile, 2-amino-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-80-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2H-tetrazol-5-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-82-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,10R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)dibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 928246-86-0 CAPLUS


CN Acetamide, 2-(acetyloxy)-N-[(2R,10R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[c,f]pyrido[1,2-a]azepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 928246-88-2 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-N-(2-hydroxyethyl)-10-methyl-2-[(2,2,2-trifluoroacetyl)amino]-, (2R,10R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:818068 CAPLUS
 DOCUMENT NUMBER: 145:249239
 TITLE: Preparation of dibenzopyridodiazepines as nonsteroidal glucocorticoid receptor modulators.
 INVENTOR(S): Plate, Ralf; Zaman, Guido Jenny Rudolf; Hermkens, Pedro Harold Han; Jans, Christiaan Gerardus Johannes Maria; Buijsman, Rogier Christian; Man, Adrianus Petrus Antonius; Conti, Paolo Giovanni Martino; Lusher, Scott James; Dokter, Willem Hendrik Abraham
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 41pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084917	A1	20060817	WO 2006-EP50906	20060214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006212192 A1 20060817 AU 2006-212192 20060214 CA 2597748 A1 20060817 CA 2006-2597748 20060214 PRIORITY APPLN. INFO.: EP 2005-101086 A 20050214 WO 2006-EP50906 W 20060214 OTHER SOURCE(S): MARPAT 145:249239 GI				




AB Title compds. [I; R1 = H, alkyl; R2 = COR15, SO2R15; R3 = H, alkyl, OR16; R4 = H, alkyl, OR16; R6 = H, CHNOR16; R7 = H, halo, cyano, (substituted) alkyl, alkenyl, alkynyl, CHNOR16, OR16, COR16, CO2R16; R8 = H, cyano, halo, NO2, (substituted) alkyl, alkenyl, alkynyl, alkoxy, (hetero)aryl, CONHR17, NHCOR20, CHNOR16, NHSO2R21, etc.; R9 = H, halo, cyano, alkyl, haloalkyl; R10 = H, alkyl; R11 = H; R12 = H, cyano, alkyl; R13 = H, alkyl, halo, formyl; R14 = H, halo, cyano, alkyl, alkenyl, COR21, (hetero)aryl; R15 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkenyloxy, heteroaryl, amino, alkylthioalkyl, alkoxyalkyl; R16 = H, alkyl, alkenyl, alkynyl; R17 = H, alkoxy, cycloalkyl, alkyl, haloalkyl, (substituted) heteroaryl; R18 = H, NH2, COR21, alkylthio; R19 = H, (substituted) alkyl; R20 = H, (substituted) alkyl, alkenyl, heteroaryl, etc.; R21 = H, alkyl], were prepared. Thus, cis-2,2,2-trifluoro-N-(8-formyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl)acetamide was prepared from 2-bromonitrobenzene, N-methylaniline, Danishefsky's diene, and Et trifluoroacetate. I showed glucocorticoid receptor activity with EC50 <2 + 10-8 M.

IT 906067-92-3P 906067-93-4P 906067-94-5P
 906067-95-6P 906067-96-7P 906067-97-8P
 906067-98-9P 906067-99-0P 906068-00-6P
 906068-01-7P 906068-02-8P 906068-03-9P
 906068-04-0P 906068-05-1P 906068-06-2P
 906068-07-3P 906068-08-4P 906068-09-5P
 906068-10-8P 906068-11-9P 906068-12-0P
 906068-13-1P 906068-14-2P 906068-15-3P
 906068-16-4P 906068-17-5P 906068-18-6P
 906068-19-7P 906068-20-0P 906068-21-1P
 906068-22-2P 906068-23-3P 906068-24-4P
 906068-25-5P 906068-26-6P 906068-27-7P
 906068-28-8P 906068-29-9P 906068-30-2P
 906068-31-3P 906068-32-4P 906068-33-5P
 906068-34-6P 906068-35-7P 906068-36-8P
 906068-37-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of dibenzopyridodiazepines as nonsteroidal glucocorticoid receptor modulators)

RN 906067-92-3 CAPUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-8-formyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906067-93-4 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-6-formyl-1,2,3,4,10,14b-hexahydro-10-methylidibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906067-94-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906067-95-6 CAPLUS

CN Acetamide, N-[(2R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906067-96-7 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-10-methyl-N-phenyl-2-[(trifluoroacetyl)amino]-, (2R,14bR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906067-97-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[(2R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906067-98-9 CAPLUS

CN Propanamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-2-[(trifluoroacetyl)amino]dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-8-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906067-99-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-2-[(trifluoroacetyl)amino]dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-8-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-00-6 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxylic acid, 1,2,3,4,10,14b-hexahydro-10-methyl-2-[(trifluoroacetyl)amino]-, ethyl ester, (2R,14bR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-01-7 CAPLUS

CN Acetamide, N-[(2R,14bR)-7-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-02-8 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-03-9 CAPLUS

CN Acetamide, N-[(2R,14bR)-14-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]iazepin-2-yl]-2,2,2-trifluoro-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-04-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitro-14-(2-pyridinyl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-05-1 CAPLUS

CN Acetamide, N-[(2R,14bR)-8,14-dicyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-06-2 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,4S,14bR)-1,2,3,4,10,14b-hexahydro-4,10-dimethyl-8-(4-pyridinyl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-07-3 CAPLUS

CN 2-Thiopheneacetamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-dimethyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-08-4 CAPLUS


CN Acetamide, N-[(2R,14bR)-7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 906068-09-5 CAPLUS
 CN Urea, N'-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 906068-10-8 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-[1-(hydroxyimino)ethyl]-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 906068-11-9 CAPLUS

CN 2-Furancarboxamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-12-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-13-1 CAPLUS

CN Acetamide, N-[(2R,14bR)-8-acetyl-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-14-2 CAPLUS

CN Acetamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2-(methylthio)-, rel-(CA INDEX NAME)


Relative stereochemistry.



RN 906068-15-3 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10,14-dimethyl-8-(2-pyrimidinyl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-16-4 CAPLUS

CN Propanamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-17-5 CAPLUS

CN Propanamide, N-[(2R,4S,14bR)-8-fluoro-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-18-6 CAPLUS

CN Acetamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-19-7 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(2-methyl-2H-tetrazol-5-yl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 906068-20-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-(2-(hydroxyimino)ethyl)-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 906068-21-1 CAPLUS

CN 4-Isioxazolecarboxamide, N-[(2R,4S,14bR)-7-chloro-1,2,3,4,10,14b-hexahydro-4,10-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 906068-22-2 CAPLUS

CN 4-Isioxazolecarboxamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-3-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-23-3 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-4-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-24-4 CAPLUS


CN Acetamide, N-[(2R,14bR)-8-(6-cyano-2-pyridinyl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 906068-25-5 CAPLUS
 CN Acetamide, N-[(2R,14bR)-8-(5-ethyl-1,2,4-oxadiazol-3-yl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 906068-26-6 CAPLUS
 CN Propanamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2-hydroxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-27-7 CAPLUS

CN Acetamide, N-[(2R,14bR)-9-chloro-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-28-8 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]odiazepine-8-carboxamide, 1,2,3,4,10,14b-hexahydro-N-(5-methoxy-3-pyridinyl)-10-methyl-2-[(trifluoroacetyl)amino]-, (2R,14bR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-29-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide,
1,2,3,4,10,14b-hexahydro-10,14-dimethyl-2-[(trifluoroacetyl)amino]-,
(3R,4aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-30-2 CAPLUS


CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-(hydroxyacetyl)-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-,
rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 906068-31-3 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxamide,
 1,2,3,4,10,14b-hexahydro-10-methyl-N-propyl-2-[(trifluoroacetyl)amino]-,
 (2R,14bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 906068-32-4 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-[5-
 (methoxymethyl)-1,2,4-oxadiazol-3-yl]-10-methyldibenzo[b,f]pyrido[1,2-
 d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-33-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-(5-methoxy-3-pyridinyl)-10-methylidibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-34-6 CAPLUS

CN Acetamide, N-[(2R,14bR)-12-cyano-1,2,3,4,10,14b-hexahydro-10-methyl-8-nitrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-35-7 CAPLUS

CN Acetamide, N-[(2R,14bR)-8,13-dibromo-1,2,3,4,10,14b-hexahydro-10,14-dimethyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-36-8 CAPLUS

CN Methanesulfonamide, N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyl-8-(4-pyridinyl)dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-37-9 CAPLUS

CN Urea, N'-[(2R,14bR)-8-cyano-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-N-methoxy-N-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 906068-38-0P 906068-39-1P 906068-40-4P
906068-41-5P 906068-42-6P 906068-43-7P
906068-44-8P 906068-45-9P 906068-46-0P
906068-47-1P 906068-48-2P 906068-49-3P
906068-50-6P 906068-51-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzopyridodiazepines as nonsteroidal glucocorticoid receptor modulators)

RN 906068-38-0 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-ol, 1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-39-1 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine, 2-azido-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-40-4 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-41-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-42-6 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-ol, 8-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-43-7 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine, 2-azido-8-bromo-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-44-8 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carboxylic acid,
1,2,3,4,10,14b-hexahydro-10-methyl-2-[(trifluoroacetyl)amino]-,
(2R,14bR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 906068-45-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carbonitrile,
2-amino-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bR)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 906068-48-2 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-8-carbonitrile,
1,2,3,4,10,14b-hexahydro-2-isocyanato-10-methyl-, (2R,14bR)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 906068-49-3 CAPLUS

CN Acetamide, N-[(2R,14bR)-8-azido-1,2,3,4,10,14b-hexahydro-10-
methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel-
(CA INDEX NAME)


Relative stereochemistry.



RN 906068-50-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(2R,14bR)-1,2,3,4,10,14b-hexahydro-8-[(hydroxyamino)iminomethyl]-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 906068-51-7 CAPLUS

CN Acetamide, N-[(2R,14bR)-8-(bromoacetyl)-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-yl]-2,2,2-trifluoro-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:818429 CAPLUS
 DOCUMENT NUMBER: 139:323545
 TITLE: Preparation of non-steroidal dibenzopyridooxazepines,
 dibenzopyridothiazepines, and dibenzopyridoazepines as
 progesterone receptor modulators
 INVENTOR(S): Hermkens, Pedro Harold Han; Lucas, Hans; Dols, Paul
 Peter Marie Antonius; Rewinkel, Johannes Bernardus
 Maria; Folmer, Brigitte Johanna Bernita
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084963	A1	20031016	WO 2003-EP50085	20030401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480940	A1	20031016	CA 2003-2480940	20030401
AU 2003224161	A1	20031020	AU 2003-224161	20030401
BR 2003008890	A	20050111	BR 2003-8890	20030401
EP 1495030	A1	20050112	EP 2003-720570	20030401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1649879	A	20050803	CN 2003-809904	20030401
JP 2005528382	T	20050922	JP 2003-582160	20030401
NZ 535546	A	20070126	NZ 2003-535546	20030401
RU 2309155	C2	20071027	RU 2004-132215	20030401
ZA 2004007667	A	20060726	ZA 2004-7667	20040922
IN 2004CN02174	A	20060303	IN 2004-CN2174	20040929
MX 2004PA09709	A	20041213	MX 2004-PA9709	20041004
NO 2004004473	A	20041029	NO 2004-4473	20041020
US 2005171087	A1	20050804	US 2005-510275	20050311
PRIORITY APPLN. INFO.:			EP 2002-76350	A 20020404
			WO 2003-EP50085	W 20030401

OTHER SOURCE(S): MARPAT 139:323545
 GI



I



II

AB Title compds. I [wherein X = O, S, CH₂, or NR₁₈; Y = O, S, or NH; R₁, R₃, R₄, R₅, and R₁₀ = independently H, halo, alkyl, alkenyl, alkynyl, OH, CN, alkoxy(carbonyl), SOO-2-(halo)alkyl, alkanoyl, or NR₁₉R₂₀; R₂ = H, halo, NO₂, NR₁₁R₁₂, alkyl, alkenyl, alkynyl, OH, alkoxy(carbonyl), or alkylthio; R₆ = H, CYR₁₅, CO₂R₁₆, CSNR₁₇, (alkoxy)alkyl, or (CH₂)_nCO₂R₂₁; R₇ = H, (halo)alkyl, (halo)alkenyl, or (halo)alkynyl; R₈ and R₈ = independently H or alkyl; R₁₁ and R₁₂ = independently H, alkyl, alkenyl, alkynyl, alkoxy-carbonyl, alkylsulfonyl, or arylsulfonyl; R₁₅ = H or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, aryl, diarylamino, aminoalkyl, hydroxyalkyl, or carboxyalkyl; R₁₆ = (halo)alkyl; R₁₇ = optionally halo-substituted (cyclo)alkyl, alkenyl, or alkynyl; R₁₈, R₁₉, and R₂₁ = independently H or alkyl; R₂₀ = H, alkyl, aryl, alkanoyl, or alkylcarbamoyl; n = 1-3; with provisos; and prodrugs and pharmaceutically acceptable salts thereof] were prepared as agonists, partial agonists, or antagonists of progesterone receptor B (PR-B). For example, acylation of (trans)-7-chloro-2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-amine maleate with 4-phenylbenzoyl chloride in the presence of DIPEA in CH₂Cl₂ provided II (44%). The (1S,14bR)-isomer of difluoroacetamide derivative was prepared similarly. In an in vitro bioassay

of

Chinese hamster ovary cells stably transfected with human PR-B expression plasmid and a reporter plasmid, the latter displayed anti-progestagenic activity with an EC₅₀ < 10 nM.

IT 613661-99-7P 613662-19-4P 613662-39-8P
613662-44-5P 613662-76-3P 613662-78-5P
613662-79-6P 613662-93-4P 613663-04-0P
613663-15-3P 613663-25-5P 613663-26-6P
613663-28-8P 613663-40-4P 613663-60-8P
613663-66-4P 613663-67-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
 (PR-B modulator; preparation of non-steroidal dibenzopyridooxazepines,
 dibenzopyridothiazepines, and dibenzopyridoazepines as progesterone
 receptor modulators)

RN 613661-99-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-fluoro-1,3,4,14b-
 tetrahydro-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-19-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 12-chloro-2,3,4,4a-
 tetrahydro-, (4R,4aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-39-8 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-
 dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA
 INDEX NAME)


Relative stereochemistry.



RN 613662-44-5 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-76-3 CAPLUS

CN Acetamide, N-[(1R,14bS)-6,7-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-78-5 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-79-6 CAPLUS


CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-8-nitro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-93-4 CAPLUS
 CN Acetamide, N-[(1R,14bS)-6-bromo-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-04-0 CAPLUS
 CN Acetamide, N-[(1R,14bS)-6-bromo-8-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-15-3 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-bromo-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-25-5 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-1,3,4,14b-tetrahydro-7-[(phenylmethyl)amino]-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-26-6 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-amino-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-28-8 CAPLUS
 CN Acetamide, N-[(1R,14bS)-12-bromo-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-40-4 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-11-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-60-8 CAPLUS
 CN Glycine, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 613663-66-4 CAPLUS
 CN Carbamic acid, [(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-67-5 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-, (1R,14bS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 613662-10-5P 613662-28-5P 613662-37-6P
 613662-38-7P 613662-40-1P 613662-41-2P
 613662-46-7P 613662-47-8P 613662-48-9P
 613662-49-0P 613662-50-3P 613662-51-4P
 613662-53-6P 613662-54-7P 613662-56-9P
 613662-57-0P 613662-58-1P 613662-59-2P
 613662-60-5P 613662-61-6P 613662-62-7P
 613662-63-8P 613662-64-9P 613662-65-0P
 613662-66-1P 613662-67-2P 613662-68-3P
 613662-69-4P 613662-70-7P 613662-71-8P
 613662-72-9P 613662-73-0P 613662-74-1P
 613662-75-2P 613662-77-4P 613662-80-9P
 613662-81-0P 613662-82-1P 613662-84-3P
 613662-85-4P 613662-86-5P 613662-87-6P
 613662-88-7P 613662-89-8P 613662-91-2P
 613663-00-6P 613663-01-7P 613663-02-8P
 613663-03-9P 613663-11-9P 613663-12-0P
 613663-13-1P 613663-14-2P 613663-22-2P
 613663-23-3P 613663-24-4P 613663-27-7P
 613663-35-7P 613663-36-8P 613663-37-9P
 613663-38-0P 613663-39-1P 613663-47-1P
 613663-48-2P 613663-49-3P 613663-52-8P
 613663-59-5P 613663-61-9P 613663-64-2P
 613663-65-3P 613663-68-6P 613663-69-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PR-B modulator; preparation of non-steroidal dibenzopyridoazepines, dibenzopyridothiazepines, and dibenzopyridoazepines as progesterone receptor modulators)

RN 613662-10-5 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-28-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-1-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-37-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-7-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




10/510,275

RN 613662-38-7 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-40-1 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrido[1,2-a]azepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-41-2 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrido[1,2-a]azepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-46-7 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2-fluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-47-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-48-9 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-49-0 CAPLUS

CN Acetamide, 2-chloro-N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-50-3 CAPLUS

CN Acetamide, 2-bromo-N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-51-4 CAPLUS

CN Acetamide, 2-amino-N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-53-6 CAPLUS

CN Butanoic acid, 4-[[[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]amino]-2,2,3,3-tetrafluoro-4-oxo-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-54-7 CAPLUS

CN Methanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-56-9 CAPLUS

CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-57-0 CAPLUS


CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrido[1,2-a]azepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-58-1 CAPLUS
 CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-59-2 CAPLUS
 CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 613662-60-5 CAPLUS
 CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-61-6 CAPLUS

CN Ethanethioamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-62-7 CAPLUS

CN Ethanethioamide, 2,2,2-trifluoro-N-[(1R,14bS)-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-63-8 CAPLUS

CN Ethanethioamide, N-[(1R,14bS)-6,7-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-64-9 CAPLUS

CN Ethanethioamide, 2-amino-N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-65-0 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-N-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-66-1 CAPLUS

CN Ethanimidamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-67-2 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, chloromethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-68-3 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 2-bromoethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-69-4 CAPLUS

CN Thiourea, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-N'-(2-methylpropyl)-, rel-(CA INDEX NAME)


Relative stereochemistry.



RN 613662-70-7 CAPLUS

CN Thiourea, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-N'-cyclohexyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-71-8 CAPLUS

CN Thiourea, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-N'-2-propenyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-72-9 CAPLUS

CN Thiourea, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-73-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-N-(2-methylpropyl)-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-74-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-N-propyl-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-75-2 CAPLUS

CN Acetamide, N-[(1R,14bS)-7,8-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-77-4 CAPLUS

CN Acetamide, N-[(1R,14bS)-8-bromo-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-80-9 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-81-0 CAPLUS

CN Acetamide, N-[(1R,14bS)-8-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-82-1 CAPLUS

CN Acetamide, N-[(1R,14bS)-8-[bis(phenylsulfonyl)amino]-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-84-3 CAPLUS

CN Acetamide, N-[(1R,14bS)-8-[bis(methylsulfonyl)amino]-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-85-4 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-8-
[(phenylsulfonyl)amino]-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-
2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-86-5 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-1-
[(trifluoroacetyl)amino]-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-8-yl]-,
1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-87-6 CAPLUS

CN Acetamide, N-[(1R,14bS)-6,7-dichloro-1,3,4,14b-tetrahydro-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-88-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-
tetrahydro-N-(2-methoxyethyl)-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-89-8 CAPLUS

CN Glycine, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-1-yl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-91-2 CAPLUS

CN Formamide, N-[(1R,14bS)-6,7-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-00-6 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-acetyl-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-01-7 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-cyano-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-02-8 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-ethenyl-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-03-9 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-1,3,4,14b-tetrahydro-6-methoxy-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-11-9 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-acetyl-8-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-12-0 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-cyano-8-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-13-1 CAPLUS

CN Acetamide, N-[(1R,14bS)-6-ethenyl-8-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-14-2 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[(1R,14bS)-8-fluoro-1,3,4,14b-tetrahydro-6-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-22-2 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-acetyl-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-23-3 CAPLUS


CN Acetamide, N-[(1R,14bS)-7-cyano-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-24-4 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-ethenyl-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-27-7 CAPLUS
 CN Propanamide, N-[(1R,14bS)-1,3,4,14b-tetrahydro-1-[(trifluoroacetyl)amino]-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-7-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 613663-35-7 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-12-cyano-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-36-8 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-12-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-37-9 CAPLUS
 CN Acetamide, N-[(1R,14bS)-12-bromo-6,7-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-38-0 CAPLUS
 CN Acetamide, N-[(1R,14bS)-12-bromo-7,8-dichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-39-1 CAPLUS
 CN Acetamide, N-[(1R,14bS)-12-bromo-6,7,8-trichloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-47-1 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-14-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-48-2 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-12-fluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-49-3 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-12,13-difluoro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-52-8 CAPLUS
 CN Acetamide, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 613663-59-5 CAPLUS
 CN Glycine, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-61-9 CAPLUS

CN Acetamide, N-[(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydrodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-64-2 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-1-carboxylic acid, 7-chloro-1,2,3,4,10,14b-hexahydro-4-oxo-, (1R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-65-3 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-4-oxodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-68-6 CAPLUS

CN Acetamide, N-[(1R,2S,14bS)-7-chloro-1,3,4,14b-tetrahydro-2-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-69-7 CAPLUS

CN Acetamide, N-[(1R,2R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 613662-04-7P, 7-Fluoro-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine 613662-05-8P, 7-Fluoro-1-(trichloroacetyl)-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine 613662-06-9P, Methyl 7-fluoro-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-


carboxylate 613662-07-0P 613662-08-1P
 613662-09-2P 613662-13-8P, 7-Chloro-3,4-dihydro-2H-
 dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine 613662-14-9P,
 7-Chloro-1-(trichloroacetyl)-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-
 d][1,4]thiazepine 613662-15-0P, Methyl 7-chloro-3,4-dihydro-2H-
 dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-1-carboxylate
 613662-16-1P 613662-17-2P 613662-18-3P
 613662-22-9P, 7-Chloro-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-
 d][1,4]oxazepine 613662-23-0P, 7-Chloro-1-(trichloroacetyl)-3,4-
 dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine 613662-24-1P,
 Methyl 7-chloro-3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-
 carboxylate 613662-25-2P 613662-26-3P
 613662-27-4P 613662-31-0P 613662-32-1P
 613662-33-2P 613662-34-3P 613662-35-4P
 613662-36-5P 613662-52-5P 613662-55-8P
 613662-83-2P 613662-92-3P 613662-96-7P
 613662-97-8P 613662-98-9P 613662-99-0P
 613663-07-3P 613663-08-4P 613663-09-5P
 613663-10-8P 613663-18-6P 613663-19-7P
 613663-20-0P 613663-21-1P 613663-31-3P
 613663-32-4P 613663-33-5P 613663-34-6P
 613663-43-7P 613663-44-8P 613663-45-9P
 613663-46-0P 613663-55-1P 613663-56-2P
 613663-57-3P 613663-58-4P 613663-70-0P
 613663-71-1P 613663-72-2P 613663-73-3P
 613663-74-4P 613663-75-5P 613663-76-6P
 613663-77-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of non-steroidal dibenzopyridooxazepines,
 dibenzopyridothiazepines, and dibenzopyridoazepines as progesterone
 receptor modulators)


RN 613662-04-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 7-fluoro-3,4-dihydro- (CA
 INDEX NAME)




RN 613662-05-8 CAPLUS

CN Ethanone, 2,2,2-trichloro-1-(7-fluoro-3,4-dihydro-2H-
 dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)- (CA INDEX NAME)




RN 613662-06-9 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-fluoro-3,4-dihydro-, methyl ester (CA INDEX NAME)




RN 613662-07-0 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-fluoro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.



RN 613662-08-1 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-fluoro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bR)-rel- (CA INDEX
 NAME)


Relative stereochemistry.



RN 613662-09-2 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
7-fluoro-1,3,4,14b-tetrahydro-, (1R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-13-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine, 7-chloro-3,4-dihydro- (CA
INDEX NAME)




RN 613662-14-9 CAPLUS

CN Ethanone, 2,2,2-trichloro-1-(7-chloro-3,4-dihydro-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-1-yl)- (CA INDEX NAME)




RN 613662-15-0 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-1-carboxylic acid,
 7-chloro-3,4-dihydro-, methyl ester (CA INDEX NAME)




RN 613662-16-1 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-1-carboxylic acid,
 7-chloro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bS)-rel- (CA INDEX
 NAME)

Relative stereochemistry.



RN 613662-17-2 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-1-carboxylic acid,
 7-chloro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bR)-rel- (CA INDEX
 NAME)


Relative stereochemistry.



RN 613662-18-3 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-1-carboxylic acid,
7-chloro-1,3,4,14b-tetrahydro-, (1R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-22-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 7-chloro-3,4-dihydro- (CA
INDEX NAME)




RN 613662-23-0 CAPLUS

CN Ethanone, 2,2,2-trichloro-1-(7-chloro-3,4-dihydro-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)- (CA INDEX NAME)




RN 613662-24-1 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-chloro-3,4-dihydro-, methyl ester (CA INDEX NAME)



RN 613662-25-2 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-chloro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bS)-rel- (CA INDEX
 NAME)


Relative stereochemistry.



RN 613662-26-3 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
 7-chloro-1,3,4,14b-tetrahydro-, methyl ester, (1R,14bR)-rel- (CA INDEX
 NAME)

Relative stereochemistry.


10/510,275



RN 613662-27-4 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
7-chloro-1,3,4,14b-tetrahydro-, (1R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613662-31-0 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine, 7-chloro-2,3,4,10-tetrahydro- (CA INDEX NAME)




RN 613662-32-1 CAPLUS

CN Ethanone, 2,2,2-trichloro-1-(7-chloro-2,3,4,10-tetrahydrodibenzo[c,f]pyrido[1,2-a]azepin-1-yl)- (CA INDEX NAME)




RN 613662-33-2 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-1-carboxylic acid, 7-chloro-2,3,4,10-tetrahydro-, methyl ester (CA INDEX NAME)




RN 613662-34-3 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-1-carboxylic acid, 7-chloro-1,2,3,4,10,14b-hexahydro-, methyl ester, (1R,14bS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 613662-35-4 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-1-carboxylic acid, 7-chloro-1,2,3,4,10,14b-hexahydro-, methyl ester, (1R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-36-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-1-carboxylic acid, 7-chloro-1,2,3,4,10,14b-hexahydro-, (1R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-52-5 CAPLUS

CN Carbanic acid, [2-[[[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-55-8 CAPLUS

CN Formamide, N-[[[(1R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-83-2 CAPLUS

CN Acetamide, N-[(1R,14bS)-8-amino-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-92-3 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 6,7-dichloro-1,3,4,14b-tetrahydro-N-(2-methoxyethyl)-, (1R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-96-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-carboxylic acid, 6-bromo-1,3,4,14b-tetrahydro-4-oxo-, (1R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613662-97-8 CAPLUS

CN Carbamic acid, [(1R,14bS)-6-bromo-1,3,4,14b-tetrahydro-4-oxo-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-98-9 CAPLUS

CN Carbamic acid, [(1R,14bS)-6-bromo-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613662-99-0 CAPLUS

CN 2H-Benzo[b]pyrido[1,2-d][1,4]benzoxazepin-1-amine, 6-bromo-1,3,4,14b-tetrahydro-, (1R,14bS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-07-3 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
6-bromo-8-fluoro-1,3,4,14b-tetrahydro-4-oxo-, (1R,14bR)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 613663-08-4 CAPLUS

CN Carbamic acid, [(1R,14bS)-6-bromo-8-fluoro-1,3,4,14b-tetrahydro-4-oxo-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-09-5 CAPLUS


CN Carbamic acid, [(1R,14bS)-6-bromo-8-fluoro-1,3,4,14b-tetrahydro-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 613663-10-8 CAPLUS
 CN 2H-Benzo[b]pyrido[1,2-d][1,4]benzoxazepin-1-amine, 13-bromo-11-fluoro-2,3,4,4a-tetrahydro-, (4R,4aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 613663-18-6 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid, 7-bromo-1,3,4,14b-tetrahydro-4-oxo-, (1R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 613663-19-7 CAPLUS
 CN Carbamic acid, [(1R,14bS)-7-bromo-1,3,4,14b-tetrahydro-4-oxo-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-20-0 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-bromo-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-ethylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-21-1 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-bromo-1,3,4,14b-tetrahydro-, (1R,14bS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-31-3 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid, 12-bromo-7-chloro-1,3,4,14b-tetrahydro-4-oxo- (CA INDEX NAME)




RN 613663-32-4 CAPLUS
 CN Carbamic acid, [(1R,14bS)-12-bromo-7-chloro-1,3,4,14b-tetrahydro-4-oxo-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-methylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 613663-33-5 CAPLUS
 CN Carbamic acid, [(1R,14bS)-12-bromo-7-chloro-1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-methylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 613663-34-6 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-4-amine, 7-bromo-12-chloro-2,3,4,4a-tetrahydro-, (4R,4aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-43-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
7-chloro-11-fluoro-1,3,4,14b-tetrahydro-4-oxo-, (1R,14bR)-rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 613663-44-8 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-11-fluoro-1,3,4,14b-tetrahydro-4-oxo-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-methylethyl ester, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-45-9 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-11-fluoro-1,3,4,14b-tetrahydro-2H-
dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, 1-methylethyl ester, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-46-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-4-amine, 7-chloro-11-fluoro-1,3,4,14b-tetrahydro-, (1R,14bS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-55-1 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine-1-carboxylic acid, 7-chloro-1,2,3,4,10,14b-hexahydro-10-methyl-4-oxo-, (1R,14bR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-56-2 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-10-methyl-4-oxodibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, methyl ester, rel- (9CI)

(CA INDEX NAME)


Relative stereochemistry.



RN 613663-57-3 CAPLUS

CN Carbamic acid, [(1R,14bS)-7-chloro-1,2,3,4,10,14b-hexahydro-10-methyldibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-yl]-, methyl ester, rel-(9Cl) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-58-4 CAPLUS


CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-1-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-10-methyl-, (1R,14bS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 613663-70-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
7-chloro-1,3,4,14b-tetrahydro-2-methyl-4-oxo- (CA INDEX NAME)



RN 613663-71-1 CAPLUS


CN Carbamic acid, (7-chloro-1,3,4,14b-tetrahydro-2-methyl-4-oxo-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 613663-72-2 CAPLUS

CN Carbamic acid, [(1R,2S,14bS)-7-chloro-1,3,4,14b-tetrahydro-2-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-73-3 CAPLUS

CN Carbamic acid, [(1R,2R,14bS)-7-chloro-1,3,4,14b-tetrahydro-2-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 613663-74-4 CAPLUS

CN Carbamic acid, [(1R,2R,14bR)-7-chloro-1,3,4,14b-tetrahydro-2-methyl-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl]-, methyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 613663-75-5 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-2-methyl-, (1R,2R,14bS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-76-6 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-2-methyl-, (1R,2R,14bR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 613663-77-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-2-methyl-, (1R,2S,14bS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 613662-43-4 613662-45-6 613662-90-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of non-steroidal dibenzopyridooxazepines, dibenzopyridothiazepines, and dibenzopyridoazepines as progesterone receptor modulators)

RN 613662-43-4 CAPLUS

CN Benzo[c]pyrido[1,2-a][1]benzazepin-1-amine, 1,2,3,4,10,14b-hexahydro-, (1R,14bS)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 613662-42-3

CMF C18 H20 N2

Relative stereochemistry.

10/510,275




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 613662-45-6 CAPLUS


CN 1H-Benzo[b]pyrido[1,2-d][1,4]benzoxazepin-4-amine, 12-chloro-2,3,4,4a-tetrahydro-, (4R,4aS)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 613662-19-4

CMF C17 H17 Cl N2 O

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.


10/510,275



RN 613662-90-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-1-amine, 7-chloro-1,3,4,14b-tetrahydro-, monohydrobromide, (1R,14bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HBr

REFERENCE COUNT:

1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

☒ ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:555345 CAPLUS
 DOCUMENT NUMBER: 139:350712
 TITLE: Synthesis of substituted dibenzoxazepines and
 dibenzthiazepine using of 4-bromo-5-
 nitrophthalonitrile
 AUTHOR(S): Abramov, Igor' G.; Smirnov, Alexey V.; Kalandadze,
 Levan S.; Sakharov, Vladimir N.; Plakhtinskii,
 Vladimir V.
 CORPORATE SOURCE: Yaroslavl State Technical University, Yaroslavl,
 150023, Russia
 SOURCE: Heterocycles (2003), 60(7), 1611-1614
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:350712
 AB Proposed a method of synthesis of new cyano containing compds. of oxazepine
 and thiazepine series based on activated aromatic nucleophilic substitution
 reaction of bromine atom and nitro group in 4-bromo-5-nitrophthalonitrile
 (I) by various bifunctional O-, N-, S-nucleophiles. For example, reaction
 of I with 2-(5-phenyl-4H-1,2,4-triazol-3-yl)phenol in DMF at 90°
 for 2 h gave 79% 3-phenylbenzo[b]-1,2,4-triazolo[4,3-d][1,4]benzoxazepine-
 6,7-dicarbonitrile.
 IT 619261-35-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of substituted dibenzoxazepines and dibenzthiazepine using
 4-bromo-5-nitrophthalonitrile)
 RN 619261-35-7 CAPLUS
 CN 15H-Benz[b]isoquino[2,1-d][1,4]benzoxazepine-11,12-dicarbonitrile,
 4b,16-dihydro-2,3-dimethoxy-6-nitro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

X ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:26781 CAPLUS
 DOCUMENT NUMBER: 138:385399
 TITLE: Synthesis of tetracyclic pyrido[2,3-b]azepine derivatives as analogues of mirtazapine via N-acyliminium ion cyclization
 AUTHOR(S): Lee, Jae Yeol; Bang, Sung Hun; Lee, Sook Ja; Song, Yun Seon; Jin, Changbae; Park, Hokoon; Lee, Yong Sup
 CORPORATE SOURCE: Division of Life Sciences, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea
 SOURCE: Bulletin of the Korean Chemical Society (2002), 23(11), 1623-1628
 CODEN: BKCSDE; ISSN: 0253-2964
 PUBLISHER: Korean Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:385399
 GI




I



Me II

AB Tetracyclic pyrido[2,3-b]azepine derivs. as analogs of mirtazapine were synthesized via N-acyliminium ion cyclization by using aromatic rings such as benzene and thiophene ring as a π -nucleophile, and evaluated for the binding affinity for α 2-adrenoceptor. Among tested compds., 2,3,9,13b-tetrahydro-1H-benzo[f]pyrrolo[2,1-a]pyrido[2,3-c]azepine (I) was the most potent ($K_i = 0.26 \mu\text{M}$) but showed about 3-fold less binding affinity than mirtazapine (II) ($K_i = 0.08 \mu\text{M}$) for α 2-adrenoceptor.
 IT 372109-46-1
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (α 2-adrenoceptor affinity of tetracyclic pyrido[2,3-b]azepine derivs. (mirtazapine analogs))
 RN 372109-46-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro- (CA INDEX NAME)



10/510,275

REFERENCE COUNT:

22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

☒ ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2001:599475 CAPLUS
 DOCUMENT NUMBER: 135:357858
 TITLE: Synthesis of tetracyclic dibenzo[c,f]azepine and benzo[f]thieno[3,2-c]azepine derivatives via N-acyliminium ion cyclization

AUTHOR(S): Lee, Jae Yeol; Baek, Nam Jun; Lee, Sook Ja; Park, Hoon; Lee, Yong Sup

CORPORATE SOURCE: Division of Life Sciences, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SOURCE: Heterocycles (2001), 55(8), 1519-1526
 CODEN: HTCYAM; ISSN: 0385-5414


PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:357858

AB Tetracyclic dibenzo[c,f]-4-oxopyrrolo[1,2-c]azepine, dibenzo[c,f]-5-oxopiperido[1,2-c]azepine, benzo[f]-4-oxopyrrolo[1,2-a]thieno[3,2-c]azepine and benzo[f]-5-oxopiperido[1,2-a]thieno[3,2-c]azepine were prepared through intramol. N-acyliminium ion cyclization of hydroxylactams with aromatic or heteroarom. rings such as benzene and thiophene as a π -nucleophile. In the case of a furan ring, the hydroxylactams were completely decomposed under the acidic conditions (formic acid or methanesulfonic acid). Subsequent reduction of dibenzo[c,f]-4-oxopyrrolo[1,2-c]azepine, dibenzo[c,f]-5-oxopiperido[1,2-c]azepine, benzo[f]-4-oxopyrrolo[1,2-a]thieno[3,2-c]azepine and benzo[f]-5-oxopiperido[1,2-a]thieno[3,2-c]azepine with $\text{BF}_3 \cdot \text{O}(\text{C}_2\text{H}_5)_2$ and $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$ finally provided the tetracyclic dibenzo[c,f]pyrrolo[1,2-c]azepine, dibenzo[c,f]piperido[1,2-c]azepine, benzo[f]pyrrolo[1,2-a]thieno[3,2-c]azepine and benzo[f]piperido[1,2-a]thieno[3,2-c]azepine derivs. as analogs of mianserin.

IT 372109-42-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tetracyclic dibenz[c,f]azepine and benzo[f]thieno[3,2-c]azepine derivs. via N-acyliminium ion cyclization)

RN 372109-42-7 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-4(1H)-one, 2,3,10,14b-tetrahydro- (CA INDEX NAME)



IT 372109-46-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of tetracyclic dibenz[c,f]azepine and benzo[f]thieno[3,2-c]azepine derivs. via N-acyliminium ion cyclization)

RN 372109-46-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro- (CA INDEX NAME)




REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

☒ ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:13540 CAPLUS
 DOCUMENT NUMBER: 132:236953
 TITLE: 1,3-Dipolar cycloaddition of azomethine ylides derived from imines and difluorocarbene to alkynes: a new active Pb-mediated approach to 2-fluoropyrrole derivatives
 AUTHOR(S): Novikov, Mikhail S.; Khlebnikov, Alexander F.; Sidorina, Elena S.; Kostikov, Rafael R.
 CORPORATE SOURCE: Department of Chemistry, St. Petersburg State University, St. Petersburg, 198904, Russia
 SOURCE: Perkin 1 (2000), (2), 231-237
 CODEN: PERKF9; ISSN: 1470-4358
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:236953
 AB Domino reactions of imines with difluorocarbene in the presence of electron-deficient alkynes lead to 2-fluoropyrrole derivs. The process involves intermediate azomethine ylide formation, its 1,3-dipolar cycloaddn. to alkyne, followed by dehydrofluorination. A modified difluorocarbene generation method using active lead for dibromodifluoromethane reduction is proposed, providing shorter reaction time and improved yields of fluoropyrroles. The reactions with monoactivated acetylenes occur regioselectively. The cycloaddn. of ylides to dipolarophiles such as phenylpropynal, whose carbonyl group is more active than the triple bond, gives rise to oxazolidine derivs., implying a change in the reaction site.
 IT 262278-93-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (1,3-dipolar cycloaddn. of azomethine ylides derived from imines and difluorocarbene to alkynes)
 RN 262278-93-3 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-1,2,3,4-tetracarboxylic acid, 10,14b-dihydro-, tetramethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 1999:688022 CAPLUS

DOCUMENT NUMBER: 132:83765

TITLE: Preliminary study on the effect of miniaturization and use of volatile mobile phases in LC for the on-line LC-MS analysis of basic pharmaceuticals

AUTHOR(S): Vervoort, R. J. M.; Debets, A. J. J.; Lamers, R. J.;

Claessens, H. A.; Jansen, J. G. M.; Cramers, C. A.

CORPORATE SOURCE: Department of Analytical Chemistry for Development, AKZO Nobel NV Oranion, Oss, 5240 BH, Neth.

SOURCE:

(1999), 21(2), 213-269

CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To enhance to compatibility of the online coupling of liquid chromatog. (LC) with mass spectrometry (MS) for the anal. of basic pharmaceuticals, the use of volatile mobile phase systems in combination with miniaturized LC was investigated. Multifactor anal. of variance (MANOVA) was used to evaluate the data obtained for the various variables (modifier, stationary phase, buffer, buffer pH and buffer concentration) on the resolution, peak

symmetry

and retention of four basic compds. analyzed using LC columns with internal diams. (I.D.) of 0.3, 1.0 and 4.6 mm (conventional). Preliminary results obtained with the investigated micro and conventional columns showed similar behavior with respect to ruggedness. The various investigated variables showed that miniaturization by simply down-scaling dimensions can result in varying selectivity and peak shapes for basic compds. When comparing volatile mobile phases (containing ammonium acetate or ammonium citrate) and a conventional non-volatile mobile phase (containing sodium phosphate) under pH 3 conditions, similar separation performances were observed. In the present study, ammonium citrate as the buffering salt, a high buffer concentration and methanol as the modifier showed the best peak

symmetry.


IT 55113-48-9

RL: ANT (Analyte); ANST (Analytical study)

(effect of miniaturization and use of volatile mobile phases in LC for the online LC-MS anal. of basic pharmaceuticals)

RN 55113-48-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

27


THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:210647 CAPLUS
 DOCUMENT NUMBER: 126:321150
 TITLE: Monitoring of new silica-based reversed-phase stationary phases for the liquid chromatographic analysis of basic pharmaceuticals using principal components analysis
 AUTHOR(S): Vervoort, R. J. M.; Derksen, M. W. J.; Debets, A. J. J.
 CORPORATE SOURCE: AKZO Nobel, NV Organon, P.O. Box 20, 5340 BH, Oss, Neth.
 SOURCE: A (1997), 765(2), 157-168
 CODEN: JCRAB1; ISSN: 0021-9673
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In this study, 14 com. available reversed-phase stationary phases were compared for the HPLC determination of basic pharmaceutical compds. The effect of silanol blocking compds. on retention and peak shape was investigated by using phosphate buffers at pH values of 3 and 7. Principal component anal. was used to analyze the data set, enabling an evaluation of the various stationary phases. The com. available stationary phases showed distinct differences in their suitability for the anal. of basic compds., whereas addition of N,N-dimethyloctylamine to mobile phase buffer at pH 3 caused an improvement in the peak shapes.
 IT 55113-48-9, Org 2566
 RL: ANT (Analyte); ANST (Analytical study)
 (monitoring of silica-based HPLC stationary phases for amine pharmaceuticals determination using principal component anal.)
 RN 55113-48-9 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




X ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 SESSION NUMBER: 1996:694175 CAPLUS
 DOCUMENT NUMBER: 125:309031
 TITLE: Antiitching compositions containing amino acids and other ingredients for atopic dermatitis
 INVENTOR(S): Endo, Masayuki; Sagya, Hiromichi; Sato, Masahiro; Iso, Toshiaki; Funayama, Nobuo; Hyama, Naoki; Umeda, Minako
 PATENT ASSIGNEE(S): Pola Kasei Kogyo Kk, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 08217695	A	19960827	JP 1995-46465	19950210
PRIORITY APPLN. INFO.:				JP 1995-46465	19950210
AB	Antiitching compns. for treatment of atopic dermatitis comprise (A) 5-40 weight% amino acids or their salts, sugars, >3 OH polyhydric alcs., polysaccharides or their salts, pyrrolidonecarboxylic acid or their salts and/or phospholipids as moisture-holding agents and (B) 0.01-5 weight% 5HT antagonists. As an example, a cream contained microcryst. wax 10, stearic acid 13, cetanol 5, squalane 20, butylparaben 0.1, 5HT antagonist 0.1, propylene glycol 5, glycerin 25, methylparaben 0.3, KOH 1.7 and water 19.8 weight parts. Clin. tests conformed their effectiveness.				
IT	55518-22-4, Dibenzo[c,f]pyrido[1,2-a]azepine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiitching compns. containing amino acids and other ingredients for atopic dermatitis)				
RN	55518-22-4 CAPLUS				
CN	Dibenzo[c,f]pyrido[1,2-a]azepine (9CI) (CA INDEX NAME)				



L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:187244 CAPLUS
 DOCUMENT NUMBER: 124:343247
 TITLE: Synthesis of 1-amino-1,2,3,14b-tetrahydro-4H-pyrido[1,2-d]dibenz[b,f][1,4]oxazepine and related compounds
 AUTHOR(S): Caulfield, Wilson L.; Gibson, Samuel; Rae, Duncan R.
 CORPORATE SOURCE: Organon Laboratories Ltd., Newhouse, Motherwell, ML1 5SH, UK
 SOURCE: 1: Organic and Bio-Organic Chemistry (1996), (6), 545-53
 CODEN: JCPRB4; ISSN: 0300-922X
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:343247
 GI



I



II

AB The synthesis is described of the epimeric 1-amino-1,2,3,14b-tetrahydro-4H-pyrido[1,2-d]dibenz[b,f][1,4]oxazepines and their N-substituted analogs. The cis-amines I (R = NH₂, NH₂Et, NMe₂) were prepared from the ketone by reduction of the corresponding oxime, whereas the trans isomers II (R₁ = H; R₂ = NH₂, NH₂Et, NMe₂) were prepared from the 1-ethoxycarbonyl derivative by

Curtius


degradation Attempts to convert the trans alc. II (R₁ = MeO, R₂ = OH) into the epimeric azido compound by an S_N2 replacement reaction with sodium azide resulted in rearrangement to give the novel ring system, 14-azido-11-methoxy-1,2,14,14a-tetrahydro-4H-pyrrolo[1,2-d]dibenz[b,g][1,4]oxazocine instead of the title compds.

IT 176716-37-3P 176716-38-4P 176716-39-5P
 176716-41-9P 176716-42-0P 176716-44-2P
 176716-48-6P 176716-49-7P 176716-57-7P
 176716-59-9P 176716-60-2P 176716-61-3P
 176716-65-7P 176716-66-8P 176716-67-9P
 176716-68-0P 176716-69-1P 176716-72-6P
 176716-74-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of 1-amino-1,2,3,14b-tetrahydro-4H-pyrido[1,2-d]dibenz[b,f][1,4]oxazepine and related compds.)

RN 176716-37-3 CAPLUS


CN 4H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-4-one, 2,3-dihydro-12-methoxy- (CA INDEX NAME)



RN 176716-38-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 1,3,4,14b-tetrahydro-12-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-39-5 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 1,3,4,14b-tetrahydro-12-methoxy-, 4-methylbenzenesulfonate (ester), cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-41-9 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 176716-42-0 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 1,3,4,14b-tetrahydro-1-[(methylthio)methoxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-44-2 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-, (1R,14bS)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 176716-43-1

CMF C17 H18 N2 O

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


10/510,275

Double bond geometry as shown.




RN 176716-48-6 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 1,3,4,14b-tetrahydro-12-methoxy- (CA INDEX NAME)




RN 176716-49-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 1,3,4,14b-tetrahydro- (CA INDEX NAME)



RN 176716-57-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 3,4-dihydro- (CA INDEX NAME)



RN 176716-59-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-, (1R,14bR)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 176716-58-8

CMF C17 H18 N2 O

10/510,275

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 176716-60-2 CAPLUS

CN Acetamide, N-(1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-61-3 CAPLUS


CN Acetamide, N-(2-chloro-1,3,4,14b-tetrahydro-2H-benzo[b]pyrido[1,2-d][1,4]benzoxazepin-1-yl)-, (1 α ,2 β ,14b β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-65-7 CAPLUS

CN Ethanone, 1-(3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-
(CA INDEX NAME)




RN 176716-66-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-1-carboxylic acid,
3,4-dihydro-, ethyl ester (CA INDEX NAME)



RN 176716-67-9 CAPLUS


CN Ethanone, 2,2,2-trichloro-1-(3,4-dihydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-
(CA INDEX NAME)



RN 176716-68-0 CAPLUS

CN Ethanone, 1-(1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-69-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-carboxylic acid, 1,3,4,14b-tetrahydro-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-72-6 CAPLUS

CN Acetamide, N-(1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-yl)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-74-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-carboxylic acid, 1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 176716-40-8P 176716-43-1P 176716-50-0P
 176716-51-1P 176716-58-8P 176716-62-4P
 176716-63-5P 176716-64-6P 176716-70-4P
 176716-71-5P 176716-73-7P 176716-75-9P
 176716-76-0P 176716-77-1P 176716-78-2P
 176716-79-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of 1-amino-1,2,3,4b-tetrahydro-4H-pyrido[1,2-d]
 dibenz[b,f][1,4]oxazepine and related compds.)

RN 176716-40-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 1,3,4,14b-tetrahydro-12-methoxy-, acetate (ester), cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-43-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/510,275

RN 176716-50-0 CAPLUS

CN 4H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-4-one, 1,2,3,14b-tetrahydro-1-hydroxy-12-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-51-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 2,3,4,4a-tetrahydro-12-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-58-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-62-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, N-ethyl-1,3,4,14b-tetrahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/510,275




RN 176716-63-5 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, N-ethyl-1,3,4,14b-tetrahydro-, (1R,14bR)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 176716-62-4
CMF C19 H22 N2 O


Relative stereochemistry.



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




RN 176716-64-6 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-70-4 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-carboxylic acid,
 1,3,4,14b-tetrahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-71-5 CAPLUS
 CN Ethanone, 1-(1,3,4,14b-tetrahydro-2H-dibenzo[b,f]pyrido[1,2-d]
 [1,4]oxazepin-1-yl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 176716-73-7 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-carboxylic acid,
 1,3,4,14b-tetrahydro-, ethyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 176716-75-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, N-ethyl-1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 176716-76-0 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, N-ethyl-1,3,4,14b-tetrahydro-, (1R,14bS)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 176716-75-9

CMF C19 H22 N2 O

Relative stereochemistry.




CM 2

10/510,275


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 176716-77-1 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 176716-78-2 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-, (1R,14bS)-rel-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 176716-77-1
CMF C19 H22 N2 O

Relative stereochemistry.




CM 2

CRN 110-16-7
CMF C4 H4 O4

10/510,275


Double bond geometry as shown.



RN 176716-79-3 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-1-ol, 2,3,4,4a-tetrahydro-12-methoxy-, acetate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:613130 CAPLUS

DOCUMENT NUMBER: 121:213130

TITLE: Selection of stationary phases for the liquid chromatographic analysis of basic compounds using chemometric methods

AUTHOR(S): Vervoort, R. J. M.; Derksen, M. W. J.; Maris, F. A.

CORPORATE SOURCE: AKZO Nobel, N.V. Organon, P.O. Box 20, BH Oss, 5340, Neth.

SOURCE: A (1994), 678(1), 1-15

CODEN: JCRAB1; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The anal. of basic compds. by means of reversed-phase liquid chromatog. is often hampered by poor peak shapes. In this paper chemometrical methods are used to select and reduce the number of test compds. and to detect differences in applicability of stationary phases designed for the anal. of basic drugs. In the first part principal component anal. was applied to reduce the number of test compds. necessary to characterize a stationary phase. From a data set of the asymmetry values of 32 test compds. analyzed on six different LC columns, five representative compds. were selected. Subsequently, these five compds. were used for evaluation of com. available columns. For the column judgement the asymmetry of the test compds., the efficiency and the short-term reproducibility of the capacity factor and the plate number, were taken into account. Graphical presentation using bar charts, multi-criteria decision making based on the Pareto optimality and bi-plots were used to distinguish between columns. First of all eight columns were compared at individual pH values of 3.0, 7.0 and 11.0. Finally, all results were combined and revealed that for these test compds. very good results were obtained at pH 11 using a column containing zirconium oxide coated with polybutadiene (3MZ-18). At low pH values good results were obtained with a Supelcosil LC-ABZ and a Zorbax Rx-C18 column. Overall it can be concluded that a chemometric approach is successfully applied for the development of a method for inhouse column testing and evaluation dedicated to the Organon type of compds. Other columns developed for the anal. of basic solutes can now be efficiently tested with the method described in this paper. Chemometric methods were useful to efficiently reduce the number of test compds. and for column evaluation. However, the final selection of a column also depends on the special requirements defined by the expert. The requirements, which are, for example, for routine quality control clearly different than for purity testing of new chemical entities in drug development, can be translated to weighing factors for the variables tested. For this the advice of the expert remains indispensable.


IT 55113-48-9

RL: ANST (Analytical study)
(model of basic drugs, in selection of HPLC columns by principal component anal.)

RN 55113-48-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)

10/510,275



L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:45862 CAPLUS

DOCUMENT NUMBER: 118:45862

TITLE: Comparison of high-performance liquid chromatographic methods for the analysis of basic drugs

AUTHOR(S): Vervoort, R. J. M.; Maris, F. A.; Hindriks, H.

CORPORATE SOURCE: Dep. Anal. Chem., Organon Int. BV, AKZO Pharma Group, P.O. Box 20. BH Oss. 5340, Neth.

SOURCE: (1992), 623(2), 207-20

CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Problems that are often encountered in the HPLC anal. of basic compds. are severe peak asymmetry and low separation efficiency. In attempting to solve these problems, one can become confused by the variety of suggestions given by the specialists and by the numerous stationary phases available. In this work, the anal. of basic drugs was studied from two directions. In both approaches a set of 32 basic drugs was used, differing in basicity, polarity and number and type of nitrogen atoms. In the first approach the effect of mobile phase additives and buffers on the performance of a single column was determined. It was found that tertiary and quaternary amines can be applied successfully as silanol blockers. The latter proved to be aggressive towards silica-based stationary phases. Addition of triethylamine showed a remarkable improvement in peak shape in different columns. Other aspects, such as pKa, retention and amount injected, were systematically studied. In the second approach, eight different columns, specially recommended for the chromatog. of basic drugs, were evaluated. The chromatog. results showed great variability. As far as peak shape as a function of pH is concerned, an electrostatically shielded stationary phase was most promising for the anal. of basic compds. This column can even be used without buffers, which can be an advantage in liquid chromatog.-mass spectrometry coupling. Because some results were inconsistent with published results, a third approach was to study three columns in more detail.


IT 145134-54-9

RL: ANT (Analyte); ANST (Analytical study)


(HPLC of, pKa effect on)

RN 145134-54-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl- (CA INDEX NAME)



L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1982:400292 CAPLUS
 DOCUMENT NUMBER: 97:292
 TITLE: Presynaptic α -block and inhibition of noradrenaline and 5-hydroxytryptamine reuptake by a series of compounds related to mianserin
 AUTHOR(S): Nickolson, Victor J.; Wieringa, Joop H.
 CORPORATE SOURCE: Org. Sci. Dev. Group, Oss, Neth.
 SOURCE: (1981), 33(12), 160-6
 CODEN: JPPMAB; ISSN: 0022-3573
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

- AB A structure-activity relationship study was undertaken for a variety of structural analogs of the tetracyclic antidepressant mianserin (I) [24219-97-4]. Presynaptic α -blocking activity in vitro was evaluated measuring the potentiation of depolarization-induced noradrenaline (II) [51-41-2] release from rat cerebral cortex slices. Inhibition of II and 5HT [50-67-9] reuptake was measured in rat hypothalamic or striatal synaptosomes, resp. Presynaptic α -blockade was only found in mols. with an overall bent shape. Flat rigid mols. or flexible ones were not active. Six-membered, chair-formed D-rings (containing the -NMe moiety) appeared better than 5- or 7-membered ones. Heteroatom substitution, but not hydroxylation or methylation, of the bridge between the two aromatic rings left presynaptic α -blockade unaffected. N-demethylation and aromatic Me- or Cl-substitution reduced presynaptic α -blockade. In pyridine ring-substituted analogs, the localization of the heteroatom appeared to be crucial. Reuptake inhibitor activity was only found in desmethylmianserin [71936-92-0]. II reuptake inhibition was found in many I analogs, especially those with an exocyclic -N(Me)₂ moiety. Structure-activity relationships for II reuptake inhibition differed from those for presynaptic α -blockade and were generally less stringent. For both properties, simple additivity relationships appeared to be absent.
- IT 81756-23-2
 RL: BIOL (Biological study)
 (hydroxytryptamine and noradrenaline reuptake by brain inhibition and presynaptic α -adrenoceptor blockade by, structure in relation to)
- RN 81756-23-2 CAPLUS
- CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10/510,275



L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1977:439453 CAPLUS

DOCUMENT NUMBER: 87:39453

TITLE: Amino-substituted 1,2,3,4,10,14b-hexahydropyridino[1,2-a]dibenz[c,f]azepines

INVENTOR(S): Van der Burg, Willem Jacob

PATENT ASSIGNEE(S): Akzona, Inc., USA

SOURCE: U.S., 13 pp. Cont. of U.S. 3,966,723.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	A	19770405	US 1976-649167	19760114
	A	19760629	US 1974-463712	19740424
	A	19771018	US 1976-649434	19760115
PRIORIT: APPLN. INFO.:			US 1974-463712	A1 19740424
			NL 1973-5811	A 19730426

GI



AB Antidepressant (no data) pyridodibenzazepines I (X = CH₂, S, O, NMe; R = 2-NH₂, 3-NH₂, 2-NHMe, 2-NMe₂, 3-NMe₂, 2-CH₂NH₂, 3-CH₂NH₂, 2-CH₂CH₂NH₂, 2-CH₂NMe₂, 3-NHMe; R₁ = H, CF₃, Cl, OH; R₂ = H, Br, OMe; R₃ = H, Me; R₄ = H, Me, OMe) were prepared; in some cases sep. axial and equatorial amine isomers were prepared. Thus, morphanthridine was treated with MeCOCH:CH₂, and 2-oxo-1,2,3,4,10,14b-hexahydropyrido[1,2-a]dibenz[c,f]azepine converted into the oxime and reduced with Na-Me₂CHOH to give I (X = CH₂, R = 2-NH₂, R₁-R₄ = H).

IT 55132-68-8P 63225-95-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amination of)


RN 55132-68-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-2-carboxylic acid, 8-chloro-1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 63225-95-6 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3-bromo-3,4,10,14b-tetrahydro-
 (9CI) (CA INDEX NAME)



IT 63225-69-4P 63225-96-7P 63225-99-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrazinolysis of)
 RN 63225-69-4 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2,3-dione, 1,4,10,14b-tetrahydro-,
 3-oxime (9CI) (CA INDEX NAME)




RN 63225-96-7 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3-(dimethylamino)-3,4,10,14b-
 tetrahydro- (9CI) (CA INDEX NAME)



RN 63225-99-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 3-[(diethylamino)methyl]-1,3,4,14b-tetrahydro- (9CI) (CA INDEX NAME)



IT 55113-31-0P 63225-70-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 55113-31-0 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carbonitrile, 1,2,3,4,10,14b-hexahydro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 63225-70-7 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-3(2H)-one, 1,4,10,14b-tetrahydro-, oxime (9CI) (CA INDEX NAME)




IT 55113-04-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oximation of)
 RN 55113-04-7 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro- (9CI)
 (CA INDEX NAME)



IT 55113-30-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction with cyanide)
 RN 55113-30-9 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-ol, 1,2,3,4,10,14b-hexahydro-,
 4-methylbenzenesulfonate (ester), trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




10/510,275

IT 55113-32-1P 63225-71-8P 63225-85-4P
63225-87-6P 63225-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of)
RN 55113-32-1 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepine, 2-azido-1,2,3,4,10,14b-hexahydro-, cis-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 63225-71-8 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-, oxime
(9CI) (CA INDEX NAME)




RN 63225-85-4 CAPLUS
CN Formamide, N-[(1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrido[1,2-a]azepin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 63225-87-6 CAPLUS


CN Formamide, N-[(1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrido[1,2-a]azepin-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 63225-94-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxamide, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 55113-29-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

RN 55113-29-6 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-ol, 1,2,3,4,10,14b-hexahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 55113-05-8P 55113-06-9P 55113-07-0P
 55113-08-1P 55113-09-2P 55113-10-5P
 55113-11-6P 55113-12-7P 55113-13-8P
 55113-14-9P 55113-15-0P 55113-16-1P
 55113-26-3P 55113-27-4P 55113-28-5P
 55113-33-2P 55113-34-3P 55113-35-4P
 55113-37-6P 55113-38-7P 55113-39-8P
 55113-40-1P 55113-41-2P 55113-42-3P
 55113-44-5P 55113-46-7P 55113-49-0P
 55113-50-3P 55113-51-4P 55113-52-5P
 55113-53-6P 55113-54-7P 55113-55-8P
 55113-56-9P 55113-58-1P 55113-61-6P
 55113-62-7P 55113-63-8P 55113-64-9P
 55113-65-0P 55113-66-1P 55113-68-3P
 55113-69-4P 55113-71-8P 55113-73-0P
 55113-74-1P 55113-75-2P 55113-82-1P
 55113-84-3P 55113-87-6P 55113-90-1P
 55132-64-4P 55132-66-6P 55132-67-7P
 55132-69-9P 55196-12-8P 63225-60-5P
 63225-72-9P 63225-73-0P 63225-74-1P
 63225-75-2P 63225-76-3P 63225-77-4P
 63225-78-5P 63225-79-6P 63225-80-9P
 63225-81-0P 63225-82-1P 63225-83-2P
 63225-84-3P 63225-86-5P 63225-88-7P
 63225-89-8P 63225-90-1P 63225-91-2P
 63225-92-3P 63225-93-4P 63225-97-8P
 63225-98-9P 63226-00-6P 63226-01-7P
 63226-02-8P 63226-03-9P 63226-04-0P
 63226-06-2P 63226-07-3P 63226-08-4P
 63226-10-8P 63226-11-9P 63226-12-0P
 63264-13-1P


RL: SPN (Synthetic preparation); PREP (Preparation of)
 (preparation of)

RN 55113-05-8 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 8-bromo-3,4,10,14b-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 55113-06-9 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 8-chloro-3,4,10,14b-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 55113-07-0 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-8-hydroxy-
 (9CI) (CA INDEX NAME)




RN 55113-08-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-8-methoxy-
 (9CI) (CA INDEX NAME)




RN 55113-09-2 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 1,3,4,14b-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 55113-10-5 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 1,3,4,14b-tetrahydro-13-methyl- (9CI) (CA INDEX NAME)




RN 55113-11-6 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 55113-12-7 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 55113-13-8 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-7,11-dimethyl- (9CI) (CA INDEX NAME)




RN 55113-14-9 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2(1H)-one, 3,4,10,14b-tetrahydro-10-methyl- (9CI) (CA INDEX NAME)




RN 55113-15-0 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2(1H)-one, 3,4,10,14b-tetrahydro-13-methoxy-10-methyl- (9CI) (CA INDEX NAME)




RN 55113-16-1 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro- (9CI) (CA INDEX NAME)




RN 55113-26-3 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-3(4H)-one, 1,2,10,14b-tetrahydro- (9CI) (CA INDEX NAME)




RN 55113-27-4 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-3(4H)-one, 1,14b-dihydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 55113-28-5 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-3(4H)-one, 1,14b-dihydro-11-methyl- (9CI) (CA INDEX NAME)




RN 55113-33-2 CAPLUS
 CN Acetonitrile, (3,4,10,14b-tetrahydrodibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-ylidene)- (9CI) (CA INDEX NAME)



RN 55113-34-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxylic acid, 1,2,3,4,10,14b-hexahydro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-35-4 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-amine, 1,2,3,4,10,14b-hexahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-37-6 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro- (9CI) (CA INDEX NAME)




RN 55113-38-7 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 55113-39-8 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-13-methyl- (9CI) (CA INDEX NAME)




RN 55113-40-1 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 55113-41-2 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-42-3 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-, (2R,14bS)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-41-2

CMF C19 H22 N2

Relative stereochemistry.



CM 2


10/510,275

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 55113-44-5 CAPLUS
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-13-methoxy-10-methyl- (9CI) (CA INDEX NAME)



RN 55113-46-7 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-49-0 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 55113-48-9
CMF C20 H24 N2

10/510,275



CM 2


CRN 74-88-4
CMF C H3 I

H₃C-I

RN 55113-50-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-51-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,13-trimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-52-5 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-
 N,N,13-trimethyl-, (2R,14bS)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX
 NAME)

CM 1

CRN 55113-51-4

CMF C20 H24 N2 S

Relative stereochemistry.




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-53-6 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-8-
 methoxy-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-54-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-7-(trifluoromethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-55-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 7-chloro-1,3,4,14b-tetrahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-56-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, trans- (9CI) (CA INDEX NAME)

10/510,275


Relative stereochemistry.



RN 55113-58-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,7,11-tetramethyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-61-6 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-3-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-62-7 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-3-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-7-(trifluoromethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-63-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 55113-64-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/510,275



RN 55113-65-0 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-,
cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-66-1 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-,
(2R,14bS)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-65-0

CMF C19 H22 N2

Relative stereochemistry.




10/510,275

CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 55113-68-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-ethanamine, 1,2,3,4,10,14b-hexahydro-,
cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-69-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-2-methanamine,
1,3,4,14b-tetrahydro-13-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-71-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-73-0 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2R,14bR)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-72-9
 CMF C21 H26 N2

Relative stereochemistry.



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-74-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-75-2 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2R,14bR)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-74-1
 CMF C20 H24 N2


Relative stereochemistry.



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-82-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxylic acid, 1,2,3,4,10,14b-hexahydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-84-3 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)


CM 1

CRN 55113-83-2
 CMF C20 H24 N2




CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7




RN 55113-87-6 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 55113-90-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 55113-89-8
 CMF C21 H26 N2




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




RN 55132-64-4 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 7-chloro-1,3,4,14b-tetrahydro- (9CI) (CA INDEX NAME)



RN 55132-66-6 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-3(4H)-one, 8-bromo-1,2,10,14b-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 55132-67-7 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-3(4H)-one, 1,2,10,14b-tetrahydro-10-
 methyl- (9CI) (CA INDEX NAME)




RN 55132-69-9 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-2-carboxylic acid,
 1,3,4,14b-tetrahydro-7-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55196-12-8 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-11,12-dimethyl- (9CI) (CA INDEX NAME)



RN 63225-60-5 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxylic acid, 1,2,3,4,10,14b-hexahydro-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 63225-72-9 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-,

10/510,275

monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 63225-73-0 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-10-methyl- (9CI) (CA INDEX NAME)




RN 63225-74-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 63225-75-2 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 63225-76-3 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-3-amine, 1,3,4,14b-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 63225-77-4 CAPLUS
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-7-ol, 2-amino-1,2,3,4,10,14b-hexahydro-10-methyl- (9CI) (CA INDEX NAME)



RN 63225-78-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 63225-79-6 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 63225-80-9 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 63225-81-0 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 63225-82-1 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-13-methoxy-N,N,10-trimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 63225-83-2 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 63225-84-3 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-3-methanamine,
 1,3,4,14b-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 63225-86-5 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-N-
 methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 63225-88-7 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-(4-
 morpholinyl)- (9CI) (CA INDEX NAME)




RN 63225-89-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 1,3,4,14b-tetrahydro-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 63225-90-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro- (9CI) (CA INDEX NAME)




RN 63225-91-2 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N-methyl- (9CI) (CA INDEX NAME)




RN 63225-92-3 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-
(9CI) (CA INDEX NAME)



RN 63225-93-4 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-3-amine, 1,3,4,14b-tetrahydro-
N,N-dimethyl-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 63225-97-8 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-
N,N,11-trimethyl-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




● 2 HCl

RN 63226-02-8 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 13-chloro-1,2,3,4,10,14b-hexahydro-10-methyl-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 63226-03-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 63226-04-0 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 63226-06-2 CAPLUS
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bR)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 63226-05-1
CMF C18 H20 Cl N3

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 63226-07-3 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-N,10-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 63226-08-4 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 13-chloro-1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/510,275



● HCl


RN 63226-10-8 CAPLUS
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-
N,10-dimethyl-, (2R,14bR)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)
CM 1
CRN 63226-09-5
CMF C19 H23 N3

Relative stereochemistry.



CM 2
CRN 110-16-7
CMF C4 H4 O4


Double bond geometry as shown.



RN 63226-11-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 13-chloro-1,2,3,4,10,14b-hexahydro-N,10-dimethyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 63226-12-0 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-hexahydro-N,10-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 63264-13-1 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine, 2-amino-1,2,3,4,10,14b-hexahydro-10-methyl-, (2R,14bS)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)


10/510,275

CM 1

CRN 63264-12-0

CMF C18 H21 N3

Relative stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1975:140210 CAPLUS
 DOCUMENT NUMBER: 82:140210
 ORIGINAL REFERENCE NO.: 82:22407a,22410a
 TITLE: Amino-substituted piperidine derivatives
 INVENTOR(S): Van der Burg, Willem J.
 PATENT ASSIGNEE(S): Akzo N. V.
 SOURCE: Ger. Offen., 48 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2420168	A1	19741121	DE 1974-2420168	19740425
NL 7305811	A	19741029	NL 1973-5811	19730426
ZA 7402620	A	19750430	ZA 1974-2620	19740424
GB 1471784	A	19770427	GB 1974-17985	19740424
BE 814180	A1	19741025	BE 1974-143606	19740425
CH 605941	A5	19781013	CH 1974-5671	19740425
CH 614955	A5	19791228	CH 1977-15901	19740425
FI 58127	B	19800829	FI 1974-1284	19740425
FI 58127	C	19801210		
SE 419867	B	19810831	SE 1974-5558	19740425
SE 419867	C	19811210		
FR 2227003	A1	19741122	FR 1974-14570	19740426
JP 50035199	A	19750403	JP 1974-47484	19740426
JP 57058350	B	19821209		
AU 7468279	A	19751030	AU 1974-68279	19740426
DK 142322	B	19801013	DK 1974-2311	19740426
DK 142322	C	19810223		
	A	19771018	US 1976-649434	19760115
SE 423235	B	19820426	SE 1977-4987	19770429
SE 423235	C	19820805		
CH 619710	A5	19801015	CH 1977-15902	19771222
CH 619711	A5	19801015	CH 1977-15903	19771222
PRIORITY APPLN. INFO.:			NL 1973-5811	A 19730426
			US 1974-463712	A3 19740424
			CH 1974-5671	19740425

GI For diagram(s), see printed CA Issue.

AB Pyridinodibenzazepine, -odiazepine, -othiazepine, and -oxazepine amino derivs., useful as antidepressants (no data), were prepared via cycloadn. of morphanthridine (I), dibenzodiazepine, dibenzothiazepine, and dibenzoxazepine with MeCOCH:CH2 (II). Thus, cycloadn. of I with II gave III (R1R2 = O), which reacted with H2NOH and the oxime reduced yielded III (R1 = NH2, R2 = H). IV (R1R2 = O), prepared from the 2-oxo derivative via oxime

formation and reduction, was hydrogenated over Pd/C, tosylated, treated with NaCN, and reduced with LiAlH4 to yield IV (R1 = H, R2 = CH2NH2).

IT 55113-04-7P 55113-05-8P 55113-06-9P
 55113-07-0P 55113-08-1P 55113-09-2P
 55113-10-5P 55113-11-6P 55113-12-7P
 55113-13-8P 55113-14-9P 55113-15-0P
 55113-16-1P 55113-26-3P 55113-27-4P
 55113-28-5P 55113-29-6P 55132-64-4P


55132-66-6P 55132-67-7P 55196-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reaction of, amino derivs. from)


RN 55113-04-7 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro- (9CI)
(CA INDEX NAME)




RN 55113-05-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 8-bromo-3,4,10,14b-tetrahydro-
(9CI) (CA INDEX NAME)




RN 55113-06-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 8-chloro-3,4,10,14b-tetrahydro-
(9CI) (CA INDEX NAME)




RN 55113-07-0 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-8-hydroxy-
(9CI) (CA INDEX NAME)




RN 55113-08-1 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-8-methoxy-
(9CI) (CA INDEX NAME)




RN 55113-09-2 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 1,3,4,14b-tetrahydro-7-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 55113-10-5 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 1,3,4,14b-tetrahydro-13-
methyl- (9CI) (CA INDEX NAME)




RN 55113-11-6 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)




RN 55113-12-7 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 55113-13-8 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro-7,11-dimethyl- (9CI) (CA INDEX NAME)




RN 55113-14-9 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2(1H)-one, 3,4,10,14b-tetrahydro-10-methyl- (9CI) (CA INDEX NAME)



RN 55113-15-0 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2(1H)-one, 3,4,10,14b-tetrahydro-13-methoxy-10-methyl- (9CI) (CA INDEX NAME)




RN 55113-16-1 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-one, 1,3,4,14b-tetrahydro- (9CI) (CA INDEX NAME)



RN 55113-29-6 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-ol, 1,2,3,4,10,14b-hexahydro-, trans-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55132-64-4 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-one, 7-chloro-1,3,4,14b-
tetrahydro- (9CI) (CA INDEX NAME)




RN 55132-66-6 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-3(4H)-one, 8-bromo-1,2,10,14b-tetrahydro-
(9CI) (CA INDEX NAME)



RN 55132-67-7 CAPLUS
 CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-3(4H)-one, 1,2,10,14b-tetrahydro-10-methyl- (9CI) (CA INDEX NAME)



RN 55196-12-8 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-one, 3,4,10,14b-tetrahydro-11,12-dimethyl- (9CI) (CA INDEX NAME)



IT 55113-30-9P 55113-31-0P 55113-32-1P
 55113-33-2P 55113-34-3P 55113-35-4P
 55113-36-5P 55113-37-6P 55113-38-7P
 55113-39-8P 55113-40-1P 55113-42-3P
 55113-43-4P 55113-44-5P 55113-45-6P
 55113-46-7P 55113-47-8P 55113-49-0P
 55113-50-3P 55113-52-5P 55113-53-6P
 55113-54-7P 55113-55-8P 55113-56-9P
 55113-57-0P 55113-58-1P 55113-59-2P


55113-60-5P 55113-61-6P 55113-62-7P
 55113-63-8P 55113-64-9P 55113-66-1P
 55113-67-2P 55113-68-3P 55113-69-4P
 55113-70-7P 55113-71-8P 55113-73-0P
 55113-74-1P 55113-75-2P 55113-76-3P
 55113-77-4P 55113-78-5P 55113-79-6P
 55113-80-9P 55113-81-0P 55113-82-1P
 55113-83-2P 55113-84-3P 55113-85-4P
 55113-86-5P 55113-87-6P 55113-88-7P
 55113-90-1P 55113-91-2P 55132-68-8P
 55132-69-9P 55196-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 55113-30-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-ol, 1,2,3,4,10,14b-hexahydro-,
 4-methylbenzenesulfonate (ester), trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-31-0 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carbonitrile, 1,2,3,4,10,14b-hexahydro-,
 cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-32-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine, 2-azido-1,2,3,4,10,14b-hexahydro-, cis-
 (9CI) (CA INDEX NAME)


10/510,275

Relative stereochemistry.



RN 55113-33-2 CAPLUS


CN Acetonitrile, (3,4,10,14b-tetrahydrodibenzo[c,f]pyrido[1,2-a]azepin-2(1H)-ylidene)- (9CI) (CA INDEX NAME)



RN 55113-34-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxylic acid, 1,2,3,4,10,14b-hexahydro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-35-4 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-36-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl


RN 55113-37-6 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro- (9CI) (CA INDEX NAME)




RN 55113-38-7 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 55113-39-8 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-13-methyl- (9CI) (CA INDEX NAME)



RN 55113-40-1 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 55113-42-3 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-, (2R,14bS)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-41-2

CMF C19 H22 N2

Relative stereochemistry.



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-43-4 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 55113-44-5 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-13-methoxy-10-methyl- (9CI) (CA INDEX NAME)



RN 55113-45-6 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 55113-46-7 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-47-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, hydrochloride, trans- (9CI) (CA INDEX NAME)

10/510,275

Relative stereochemistry.




● x HCl

RN 55113-49-0 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 55113-48-9
CMF C20 H24 N2




CM 2

CRN 74-88-4
CMF C H3 I

H₃C-I

RN 55113-50-3 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-52-5 CAPLUS
 CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,13-trimethyl-, (2R,14bS)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-51-4

CMF C20 H24 N2 S

Relative stereochemistry.




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-53-6 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-8-methoxy-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-54-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-7-(trifluoromethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-55-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-2-amine, 7-chloro-1,3,4,14b-tetrahydro-N,N-dimethyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-56-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, trans- (9CI) (CA INDEX NAME)

10/510,275


Relative stereochemistry.



RN 55113-57-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 55113-58-1 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-2-amine, 1,3,4,14b-tetrahydro-N,N,7,11-tetramethyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-59-2 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-13-methoxy-N,N,10-trimethyl-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 55113-60-5 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 55113-61-6 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-3-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-62-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-3-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-7-(trifluoromethyl)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



10/510,275

RN 55113-63-8 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 55113-64-9 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-66-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-, (2R,14bS)-rel-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)


CM 1

CRN 55113-65-0

CMF C19 H22 N2

Relative stereochemistry.

10/510,275




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 55113-67-2 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-3-methanamine,
1,3,4,14b-tetrahydro-11-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-68-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-ethanamine, 1,2,3,4,10,14b-hexahydro-,
cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-69-4 CAPLUS


CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-2-methanamine,
1,3,4,14b-tetrahydro-13-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-70-7 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-ethanamine, 1,2,3,4,10,14b-hexahydro-
(9CI) (CA INDEX NAME)



RN 55113-71-8 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-73-0 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2R,14bR)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-72-9
 CMF C21 H26 N2

Relative stereochemistry.



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 55113-74-1 CAPLUS
 CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-75-2 CAPLUS


CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2R,14bR)-rel-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-74-1

CMF C20 H24 N2

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 55113-76-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 8-bromo-1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-77-4 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-(4-morpholinyl)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-78-5 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine, 1,3,4,14b-tetrahydro-2-(1-pyrrolidinyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-79-6 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-2-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-

10/510,275

, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-80-9 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N-methyl-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55113-81-0 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepin-3-amine, 1,3,4,14b-tetrahydro-N,N-dimethyl-7-(trifluoromethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 55113-82-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-carboxylic acid, 1,2,3,4,10,14b-

10/510,275


hexahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 55113-83-2 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 55113-84-3 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)

CM 1

CRN 55113-83-2


CMF C20 H24 N2




CM 2

10/510,275


CRN 88-89-1
CMF C6 H3 N3 O7




RN 55113-85-4 CAPLUS
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepin-3-amine, 1,3,4,14b-tetrahydro-N,N,11-trimethyl- (9CI) (CA INDEX NAME)



RN 55113-86-5 CAPLUS
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-3-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl- (9CI) (CA INDEX NAME)




RN 55113-87-6 CAPLUS
CN Dibenzo[c,f]pyrido[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 55113-88-7 CAPLUS

CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-N,N,10-trimethyl-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl


RN 55113-90-1 CAPLUS

CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-N,N-dimethyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 55113-89-8

CMF C21 H26 N2



CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 55113-91-2 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine-3-methanamine,
N,N-diethyl-1,3,4,14b-tetrahydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55132-68-8 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-2-carboxylic acid,
8-chloro-1,3,4,14b-tetrahydro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55132-69-9 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-2-carboxylic acid,
1,3,4,14b-tetrahydro-7-methyl-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 55196-11-7 CAPLUS

CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine-2-amine, 1,3,4,14b-tetrahydro-
N,N-dimethyl-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl

10/510,275

=> => d his

(FILE 'HOME' ENTERED AT 09:57:38 ON 14 NOV 2007)

FILE 'REGISTRY' ENTERED AT 09:57:50 ON 14 NOV 2007

L1 STRUCTURE UPLOADED
L2 9 S L1
L3 469 S L1 SSS FUL
L4 449 S L3 AND CAPLUS/LC
L5 20 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 09:58:59 ON 14 NOV 2007

L6 16 S L3


FILE 'REGISTRY' ENTERED AT 10:01:23 ON 14 NOV 2007

=> d 15 20

10/510,275

L5 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 55113-72-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-
N,N-dimethyl-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H26 N2
CI COM
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275


L5 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 696577-14-7 REGISTRY
ED Entered STN: 20 Jun 2004
CN Dibenzo[c,f]pyrido[1,2-a]azepin-3-amine, 1,2,3,4,10,14b-hexahydro- (CA
INDEX NAME)
MF C18 H20 N2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 622787-88-6 REGISTRY
ED Entered STN: 02 Dec 2003
CN 2H-Benz[b]isoquino[2,1-d][1,4]benzoxazepine (9CI) (CA INDEX NAME)
MF C21 H15 N O
CI RPS
SR CA Index Guide or Ring Systems Handbook




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 613662-42-3 REGISTRY
ED Entered STN: 07 Nov 2003
CN Dibenzo[c,f]pyrido[1,2-a]azepin-1-amine, 1,2,3,4,10,14b-hexahydro-,
(1R,14bS)-rel- (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H20 N2
CI COM
SR CA

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 63264-12-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine, 2-amino-1,2,3,4,10,14b-hexahydro-
10-methyl-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 N3
CI COM

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 63226-09-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 1,2,3,4,10,14b-hexahydro-
N,10-dimethyl-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H23 N3
CI COM

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 63226-05-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepin-2-amine, 7-chloro-1,2,3,4,10,14b-
hexahydro-10-methyl-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H20 Cl N3
CI COM


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275


L5 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 55518-21-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[b,f]pyrido[1,2-d][1,4]diazepine (9CI) (CA INDEX NAME)
MF C17 H12 N2
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275


L5 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 55518-20-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]thiazepine (9CI) (CA INDEX NAME)
MF C17 H13 N S
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275


L5 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 55518-19-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Dibenzo[b,f]pyrido[1,2-d][1,4]oxazepine (9CI) (CA INDEX NAME)
MF C17 H13 N O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/510,275

L5 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 55113-89-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Dibenzo[c,f]pyrido[1,2-a]azepine-2-methanamine, 1,2,3,4,10,14b-hexahydro-
N,N-dimethyl- (9CI) (CA INDEX NAME)
MF C21 H26 N2
CI COM
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT